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Identiﬁcation of signaling pathways in tumor cells able
to promote growth and survival of the malignant cells
are important for targeted treatment of cancers. Multi-
ple myeloma is a cancer caused by clonal expansion of
malignant plasma cells that are usually conﬁned to the
bone marrow. Isolated primary myeloma cells only
rarely grow or survive outside of the bone marrow
microenvironment. A number of growth and anti-
apoptotic factors, including interleukin-6 (IL-6), have
been implicated in sustaining the malignant myeloma
cells (1).
Some 10 yr ago, we found that hepatocyte growth
factor (HGF) may play a role in multiple myeloma, a
ﬁnding later conﬁrmed by various techniques in differ-
ent laboratories. The main results were that myeloma
cells produce HGF (2, 3), and that high serum levels of
HGF at diagnosis correlated with poor prognosis for
patients (4). Compared to healthy controls, bone
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tained high levels of HGF (5). However, also in healthy
persons, HGF could be detected, both in bone marrow
plasma and serum. It has previously been shown by us
and others that myeloma cells express the HGF-recep-
tor c-Met (2, 3, 6, 7).
Recently, HGF and c-Met have been found to be sig-
niﬁcantly dysregulated in gene expression proﬁling experi-
ments on puriﬁed plasma cells from multiple myeloma
patients. HGF was the only growth factor among 70
highly expressed genes in malignant plasma cells com-
pared to normal bone marrow plasma cells (8), and HGF
and IL-6 were also shown to characterize one of four
clusters of hyperdiploid myeloma (9). Furthermore, in a
study comparing transcriptional signatures between cells
from patients with multiple myeloma, chronic lympho-
cytic leukaemia, and Waldenstro ¨ ms macroglobulinaemia,
both HGF and MET as well as the receptor for IL-6,
were on the list of genes distinguishing myeloma from the
latter two conditions (10). Despite these ﬁndings, HGF
generally appears to be a weak growth factor for mye-
loma cells in vitro. Though there are exceptions (6, 11,
12), when tested for ability to induce cell proliferation or
prevent apoptosis in a large number of myeloma cell lines
or primary myeloma cells, HGF generally have had
limited effects (H. Hov and M. Børset, unpublished data).
MET was ﬁrst cloned as a transforming gene from a
chemically transformed osteosarcoma cell line (13), later
HGF was identiﬁed as the only known ligand for c-Met
(14). c-Met signaling is essential for fetal development,
wound healing, and tissue regeneration in the adult
organism (15–20). Aberrant c-Met signaling has been
implicated in a large number of tumors (21, 22). The
receptor has been suggested to be important in creating
or maintaining a more malignant phenotype (23). c-Met
tyrosine kinase activation initiates complex downstream
signaling cascades involving several intracellular signaling
pathways. Such signaling pathways may however, be
shared by several receptor tyrosine kinases, and substan-
tial crosstalk may exist between signaling pathways
downstream of diverse receptors. Thus, under certain cir-
cumstances, the signal from one receptor tyrosine kinase
may be replaced with the signal from another receptor,
or the signals from two receptor kinases may act in con-
cert and potentiate each other.
Here, we present data indicating that c-Met signaling
promotes growth-stimulatory signaling from IL-6. Thus,
in myeloma cells, the presence of c-Met signaling may be
necessary to obtain full effect of other growth factors.
Conversely, IL-6 is also necessary to obtain full effect of
HGF in cell migration by increasing expression of
HGF’s receptor c-Met. The results suggest that targeting
c-Met signaling may attenuate cell proliferation induced
by other growth factors such as IL-6, and may therefore
represent a novel approach to cancer treatment also in
cancers that at ﬁrst sight seem independent of c-Met
signaling.
Materials and methods
Reagents
Recombinant human IL-6 was from R&D Systems
(Abingdon, UK). HGF was puriﬁed from the human
myeloma cell line JJN-3 as described previously (3) or
purchased from PeproTech EC Ltd (London, UK). The
c-Met tyrosine kinase inhibitor PHA-665752 (24) was a
kind gift from J. G. Christensen (Pﬁzer Inc., New York,
NY, USA). The Shp2 inhibitor NSC-87877 and the
MEK1⁄2 inhibitors PD98059 and U126 were from
Merck Chemicals Ltd (Nottingham, UK). The following
c-Met antibodies were used: clone DL-21 from Upstate
(Waltham, MA, USA); Met (25H2) and anti-phospho-
Tyr
1349c-Met from Cell Signaling Technology (Beverly,
MA, USA); Fluorescein isothiocyanate (FITC) labeled
anti-human c-Met, eBioclone 97, from eBioscience
(San Diego, CA, USA); the neutralizing antibody clone
95309 from R&D Systems. Anti-Shp2, anti-phospho-
Tyr
542Shp2, anti-phospho-Tyr
580Shp2, and anti-Gab1
were from Upstate (Lake Placid, NY, USA). Anti-phos-
pho-Ser
473Akt, anti-phospho-Tyr
705STAT3, anti-STAT3,
anti-phospho-Thr
202⁄phospho-Tyr
204-p44⁄42 MAPK, anti-
p44⁄42 MAPK, anti-phospho-Tyr
307Gab1, and anti-phos-
pho-Tyr
627Gab1 were from Cell Signaling Technology.
Anti-GAPDH was from Abcam (Cambridge, UK).
Rabbit anti-HGF serum was raised by us as previously
described (4).
Cell lines and primary patient samples
ANBL-6 cells and INA-6 cells were kind gifts from Dr
Diane Jelinek (Mayo Clinic, Rochester, MN, USA)
and Dr Martin Gramatzki (University of Erlangen-
Nuremberg, Erlangen, Germany), respectively. OH-2
and IH-1 were established in our laboratory as
described previously (25, 26). Cell lines were grown in
RPMI 1640 with 10% fetal calf serum (FCS) or
human serum (OH-2 and IH-1), 2 mmol⁄L l-gluta-
mine, and 40 lg⁄mL gentamicin (complete medium)
and 1 ng⁄mL IL-6.
CD138-positive cells were puriﬁed from left over mate-
rial from bone marrow aspirates taken for diagnostic
purposes by immunomagnetic separation (27). Myeloma
cells were puriﬁed using Macs MicroBeads (Miltenyi Bio-
tec, Auburn, CA, USA). The use of bone marrow aspi-
rates for this purpose was approved by the regional
ethics committee and by informed consent from the
patients.
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Cells were washed four times in Hank’s balanced salt
solution (HBSS), seeded in 96-well plastic culture
plates (Corning Costar, Corning, NY, USA) at
1–10 · 10
4 cells⁄well in 200 lL of 0.1% bovine serum
albumin (BSA) (cell lines) or 1% FCS (primary cells) in
RPMI 1640 with 2 mmol⁄L l-glutamine, and 40 lg⁄mL
gentamicin (serum-free media). After 48 h 1 lCi of
methyl-[
3H]thymidine (NEN Life Science Products, Bos-
ton, MA, USA) was added per well and cells were har-
vested either 6 or 18 h later with a Micromate 96-well
harvester (Packard, Meriden, CT, USA). ß-radiation was
measured with a Matrix 96 ß counter (Packard).
Migration assay
INA-6 cells were washed four times in HBSS, resus-
pended in serum-free media, and seeded (2 · 10
6 cells⁄-
well) in the top compartments of polycarbonate
transwells (pore size, 5 lm; Corning Costar). The total
volume was 100 lL in the top compartments and 600 lL
in the bottom compartment. All samples were performed
in duplicates. After 18 h, the number of cells that had
migrated through the membrane to the bottom chamber
was determined by a Coulter Counter Z1 (Beckman
Coulter, Fullerton, CA, USA).
Immunoblotting
Cells were washed four times in HBSS and seeded at
10
6 cells⁄mL in serum-free media with or without cyto-
kines. PHA-665752 was added 15–30 min prior to cyto-
kines. To detect phosphorylated Gab1, Shp2, and c-Met in
ANBL-6, cells were depleted of FCS and IL-6 by four
washes in HBSS, and seeded at 10
6 cells⁄mL in RPMI
1640 with 0.1% BSA and a 1 : 750 dilution of rabbit anti-
HGF serum over night. Cells were then washed four times
in HBSS and seeded in 0.25 mL of RPMI 1640 with 0.1%
BSA in 24-well plates (4 · 10
6 cells⁄well). PHA-665752
was added to the wells (were indicated) 15 min before
incubation with HGF or IL-6 for 10 min. Then, cells were
counted by a Coulter Counter Z1 (Beckman Coulter, Ful-
lerton, CA, USA), pelleted, and resuspended in 20 lL lysis
buffer (11) per 500 000 cells. Thereafter, immunoblotting
was performed as previously described (11).
Flow cytometry
Cells were washed four times in HBSS and seeded at a
concentration of 250 000⁄mL in serum-free media. After
overnight incubation with cytokines, cells were labeled
with 0.25 lg FITC-conjugated anti-c-Met antibody (eBio-
science, San Diego, CA, USA. Catalog number 11-8858)
or 0.25 lg FITC-conjugated isotype control antibody
(Cat. no. 11-4301). Viable cells were gated from the for-
ward-, side-scatter dot plot, and analyzed for ﬂuorescence.
Ras activation assay
Ras activation was measured with a Ras activation kit
(Stressgen Bioreagents, Victoria, BC, Canada) according
to the manufacturer’s protocol. Brieﬂy, ANBL-6 cells were
washed four times in HBSS and serum starved for 4 h,
incubated with 200 nm PHA-665752 for 30 min, and then
stimulated with cytokines for another 10 min. Cells were
pelleted and lysed in buffer containing Complete Mini
protease inhibitor tablets (Roche, Basel, Switzerland). Ly-
sates from 6 · 10
6 cells were incubated with 80 lgo fa
Glutathion S-transferase fusion protein containing the
Ras binding domain of Raf1. Lysates were thereafter
placed on an immobilized glutathione disc on a spin col-
umn for 1 h at 4 C with gentle rocking. The columns were
washed and eluted with 50 lL SDS sample buffer contain-
ing b-mercaptoethanol. Twenty-ﬁve microlitre of sample
were subjected to gel electrophoresis and Western blotting,
and membranes were probed with a speciﬁc Ras antibody.
Unfractionated lysates were similarly subjected to immu-
noblotting to control total amount of Ras.
Fluorescent in situ hybridization analysis
Cytospin slides were used for ﬂuorescent in situ hybrid-
ization (FISH) analysis. Hybridization was performed
using standard procedure (Vysis, Downers Grove, IL,
USA). Thereafter, cells were counterstained with DAPI
(Vysis) and scored using a Nikon Eclipse 90i epiﬂuores-
cence microscope with PlanApo VC 60x⁄1.4oel (Nikon
Instruments Europe, Badhoevedorp, the Netherlands),
and software CytoVision version 3.7 Build 58, 2005
(Applied Imaging, San Jose, CA, USA). Information on
probes is available in a Table S1.
Statistics
The statistical signiﬁcance was determined using two-
tailed, unpaired Student’s t-test. The minimal level of sig-
niﬁcance was P = 0.05.
Results
IL-6 augmented HGF-effects by increasing c-Met
expression
Even though HGF activates c-Met in INA-6 cells (11) the
effects of HGF on cell proliferation in this cell line are
moderate. Thus, in the absence of other growth factors,
HGF-induced proliferation was limited (Fig. 1A). Inter-
estingly, the presence of HGF together with IL-6 potenti-
ated cell proliferation compared to the proliferation
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effects in migration of INA-6 cells (28) (Fig. 1B), while
there was no migration after IL-6 treatment. However, IL-
6 increased migration by HGF substantially.
A simple explanation for these ﬁndings could be that
HGF receptor expression was low and rate limiting for
HGF signaling. Indeed, after 20-h treatment with IL-6
the expression of c-Met protein in INA-6 was elevated
compared to the expression in untreated cells (Fig. 1C).
The presence of HGF downregulated c-Met expression
as this study and many other studies also have shown
previously (29). Similar results were obtained when
c-Met cell surface expression was analyzed by ﬂow
cytometry. Cells treated with IL-6 (Fig. 1D lower panel)
had higher surface expression of c-Met than untreated
cells (Fig. 1D upper panel). Also in the myeloma cell
lines OH-2 (Fig. 2A,B) and IH-1 (Fig. 2C,D) similar
results were seen: HGF alone did not increase prolifera-
tion but potentiated the effect of IL-6, and likewise,
incubation with IL-6 increased the expression of c-Met.
Inhibition of c-Met signaling reduced IL-6-induced
proliferation
We have previously demonstrated an autocrine HGF-c-
Met loop promoting growth of the myeloma cell line
ANBL-6 (11). However, under serum-free conditions there
was almost no baseline proliferation in ANBL-6 cells, sug-
gesting that the HGF-c-Met loop could not sustain prolif-
eration on its own (Fig. 3A). IL-6 promoted growth of the
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Figure 1 Synergistic effects between HGF and IL-6 in proliferation and migration of INA-6 cells. (A) INA-6 cells were grown in serum-free media
with IL-6 and HGF as indicated for 3 d before estimation of DNA synthesis. Error bars represent SEM of triplicate measurements. * Denotes sta-
tistically signiﬁcant difference from the IL-6 alone situation (P < 0.05). (B) INA-6 cells were seeded in the top wells of transwell migration cham-
bers. HGF was added to the bottom wells and IL-6 to both top and bottom wells. After 18 h, migration was determined as described in Materials
and methods. Error bars represent SEM of duplicate measurements. #Denotes statistical signiﬁcant difference between HGF with or without IL-6
was not reached (P-value = 0.14). (C) INA-6 cells were grown in serum-free media with or without 100 ng⁄mL HGF or 1 ng⁄mL IL-6 over night,
then harvested, lysed, and subjected to gel electrophoresis and Western blotting. The membrane was probed with an anti-c-Met antibody and a
GAPDH antibody as loading control. (D) INA-6 cells were grown in serum-free media with or without 1 ng⁄mL IL-6 over night, labeled with FITC-
conjugated antibody against c-Met or isotype control antibody and subjected to ﬂow cytometry analysis. Upper panel – untreated cells labeled
with FITC-c-Met antibody (bold line) compared with isotype control antibody (thin line); lower panel – c-Met expression in IL-6 treated cells (bold
line) compared to untreated cells (thin line).
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c-Met signaling with the speciﬁc c-Met tyrosine kinase
inhibitor, PHA-665752, in the presence of IL-6 gave a
potent and dose-dependent reduction in cell proliferation
(Fig. 3A). To conﬁrm that c-Met activation was important
for IL-6-induced proliferation, the kinase inhibitor was
replaced by an antibody blocking HGF binding to c-Met
(Fig. 3B). The antibody reduced IL-6-induced prolifera-
tion to a similar extent as did the c-Met kinase inhibitor.
Taken together, the results indicate that IL-6 is dependent
on c-Met signaling for full growth promotion also in the
ANBL-6 cell line. However, there were no clear differences
in c-Met expression after IL-6 treatment in these cells
(Fig. 3C), indicating that some other mechanism than
receptor upregulation is responsible for the dependency on
c-Met signaling in IL-6-induced proliferation.
IL-6-induced proliferation was dependent on activated
c-Met in some primary myeloma cells
We found nine primary isolates out of 12 tested that
responded reasonably well to IL-6 in the presence of
HGF. As often is the case with primary myeloma
samples, the DNA synthesis between samples showed
considerable variation. Inhibiting c-Met with PHA-
665752 reduced IL-6-induced proliferation in six sam-
ples (Fig. 4A, MM1–MM6); however, in two of the
samples the changes were minor (MM1 and MM2).
These results suggest that c-Met signaling is required
for full effect of IL-6 also in some primary myeloma
cells. In two of the samples (MM8 and MM9), IL-6-
induced proliferation was not affected by the presence
of the c-Met inhibitor. IL-6 can therefore also promote
cell proliferation independently of c-Met. The expres-
sion of c-Met was only examined in four of the
patients because of limited amounts of cells (Fig. 4B).
The level of c-Met was low in untreated cells but
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Figure 2 HGF potentiated IL-6-induced proliferation in OH-2 and IH-1
cells. OH-2 (A) and IH-1 (C) cells were grown in serum-free media
with or without IL-6 and HGF as indicated for 3 d before estimation of
DNA synthesis. Error bars represent SEM of triplicate measurements.
OH-2 (B) and IH-1 (D) were grown in serum-free media with or with-
out 1 ng⁄mL IL-6 over night, then harvested, lysed, and subjected to
gel electrophoresis and Western blotting. The membrane was probed
with an anti-c-Met antibody and a GAPDH antibody as loading control.
* Denotes statistically signiﬁcant difference from the IL-6 alone situa-
tion (P < 0.05).
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Figure 3 Inhibition of c-Met signaling reduced IL-6-induced prolifera-
tion in ANBL-6 cells. (A and B) ANBL-6 cells were grown in serum-
free media for 3 d with combinations of different concentrations of
IL-6 and the c-Met tyrosine kinase inhibitor PHA-665752 or 10 lg⁄mL
of an antibody blocking HGF binding to c-Met or 10 lg⁄mL of a
control antibody of the same isotype before estimation of DNA syn-
thesis. The concentration of PHA-665752 in B was 200 nM. Error bars
represent SEM of triplicate measurements. In (A) incorporation of
thymidine at 50 and 100 nM PHA-665752 were statistically signiﬁcant
different from the control at IL-6 concentrations above 0.1 ng⁄mL. In
(B) * denotes statistically signiﬁcant difference from the control or
IgG-treatment (P < 0.05). (C) ANBL-6 cells were grown in serum-free
media with or without 1 ng⁄mL IL-6 over night. Immunoblots were
probed with antibodies against c-Met and GAPDH.
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MM4, which is similar to the results obtained with the
INA-6, OH-2, and IH-1 cell lines. There seemed to be
no increase in c-Met expression after IL-6 stimulation
in the patient sample MM3 despite dependence on c-
Met in IL-6-induced proliferation in these cells. This is
similar to ﬁndings in the ANBL-6 cell line suggesting
other mechanisms for synergy between IL-6 and HGF
than IL-6-induced upregulation of c-Met expression. In
the patient sample MM9, the IL-6-induced proliferation
was not dependent on c-Met signaling, and there was
no increase of c-Met expression after IL-6 treatment
(Fig. 4A,B). Because elevated HGF expression has been
reported to characterize a subgroup of the hyperdiploid
myeloma patients, we analyzed some of the most com-
mon genetic aberrations in our primary samples by
FISH (Table 1 and Materials and methods). Of the
responders, two had IgH translocations while one had
not. Response to c-Met inhibition was therefore not
dependent on the presence or absence of an IgH trans-
location. None of the non-responding patients was
positive for IgH tranlocations.
IL-6-activation of Ras-MAPK signaling was c-Met
dependent
As IL-6 did not change c-Met expression in ANBL-6
(Fig. 3C), we decided to further examine the intracellu-
lar pathways involved in potentiation of IL-6-induced
proliferation by c-Met in this cell line. Cells were
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Figure 4 Inhibition of c-Met by PHA-665752
reduced the effects of IL-6-induced proliferation
in puriﬁed primary myeloma cells. (A) Puriﬁed
primary myeloma cells were grown with or
without IL-6 or 50 ng⁄mL HGF in combination
with 100 nM PHA-665752 (PHA). The concentra-
tions of IL-6 were 0.1 ng⁄mL for MM2,
0.5 ng⁄mL for MM8 and 1 ng⁄mL for the rest.
DNA synthesis was estimated after 2 or 3 d.
Error bars represent SEM of triplicate measure-
ments. #The difference in thymidine incorpora-
tion between IL-6 with or without PHA-665752
did not reach statistic signiﬁcance as P-values
were 0.13 and 0.08 for MM1 and MM2 respec-
tively. *Denotes statistically signiﬁcant differ-
ence from IL-6 without PHA-665752 (P < 0.05).
(B) Western blots of cells from the patients
MM2, 4, 3, and 9 are presented from left to
right. Cells were treated the same way as in
the thymidine incorporation assays except that
serum was omitted and cells lysed after 18 h of
incubation. The level of c-Met expression was
determined by Western blotting. An anti-GAP-
DH antibody was used as loading control.
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PHA-665752 reduced the modest phosphorylation of
p44⁄42-MAPK in the control wells (Fig. 5A, top panel,
lanes 1 and 2), indicating that the autocrine HGF acti-
vated p44⁄42-MAPK weakly. Adding IL-6 increased
p44⁄42-MAPK phosphorylation substantially. When
cells were treated with the c-Met tyrosine kinase inhibi-
tor PHA-665752 there was almost complete abrogation
of IL-6-induced phosphorylation of p44⁄42 MAPK
(lane 4 vs. lane 3). Similarly, the antibody blocking
HGF binding to c-Met inhibited IL-6 induced p44⁄42
MAPK phosphorylation (lane 5 vs. lane 3) in a similar
manner as PHA-665752. Taken together, the results
indicate that IL-6 was dependent on c-Met signaling
for full activation of p44⁄42 MAPK. In contrast, IL-6-
induced phosphorylation of STAT3 (Fig. 5A, middle
panel) was independent of the c-Met inhibitor PHA-
665752 and the antibody inhibiting HGF binding to c-
Met.
The p44⁄42 MAPK are downstream targets of active
Ras. As seen in Fig. 5B, Ras activation by IL-6 was also
dependent on c-Met signaling as PHA-665752 reduced
the effect of IL-6 substantially. Thus, the dependency on
c-Met in IL-6-mediated p44⁄42 MAPK activation is a
consequence of dependency on c-Met in IL-6-mediated
Ras activation. Taken together, the results suggest that
the basis for the potentiating role of c-Met signaling on
IL-6-induced proliferation is upstream of Ras.
In analogy with previous reports (30), we found that
the Ras-MAPK pathway was important for proliferation
of ANBL-6 cells because the MEK1⁄2-inhibitors
PD98059 and U126 both inhibited proliferation in these
cells (Fig. 5C).
IL-6 was dependent on c-Met for phosphorylation of
Gab-1 and Shp2
The results above indicated that molecules upstream of
Ras are possible mediators of the synergy between HGF
and IL-6 in inducing proliferation in ANBL-6 cells.
Among candidate molecules in this pathway are the tyro-
sine phosphatase Shp2 and the adaptor molecule Gab-1
(31). In Fig. 6A,B, we examined the ability of HGF and
IL-6 to induce phosphorylation of Gab1 and Shp2 in
ANBL-6 cells. Because these cells produce HGF endoge-
Table 1 Genetic aberrations in patient samples
Sample
IgH
split t(11;14) t(4;14) del13 del17 t(6;14) t(14;16)
Sample
taken
M M 1 10 00 01 0 D
MM2 R
MM3 R
MM4 1 1 0 0 0 D
MM5 0 0 0 D
MM6 D
MM7 0 0 0 D
MM8 0 0 0 D
MM9 0 0 1 0 D
Empty cells, not determined; 1, present; 0, absent; D, at diagnosis; R,
at relapse.
Ctr           IL-6  A 
B C 
PHA-665752           +           + 
c-Met antibody                            + 
phospho p44/42 MAPK 
pSTAT3 
p44/42 MAPK 
Ctr        IL-6 
PHA-665752         +            + 
GTP-Ras 
Total Ras 
0 6.3/1.3  12.5/2.5  25/5 
0 
5000 
10 000 
15 000  DMSO 
PD98059
U126 
* 
* 
*  * 
* * 
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Figure 5 c-Met signaling was necessary for IL-6-induced activation of the Ras-MAPK pathway in ANBL-6 cells. (A) ANBL-6 cells were washed
and serum starved for 4 h allowing endogenous HGF-production, preincubated with 200 nM PHA-665752 or 2 lg⁄mL of an antibody blocking HGF
binding to c-Met for 30 min and stimulated with 1 ng⁄mL IL-6 for 10 min. Cells were lysed and subjected to Western blotting. Membranes were
probed with antibodies against phospho-p44⁄42 MAPK or phospho-STAT3 tyr 705, stripped and reprobed with an antibody against total p44⁄42
MAPK. (B) Lysates from ANBL-6 were made as in (A) and subjected to afﬁnity precipitation with a Raf1-Ras binding domain-GST fusion protein to
pull down GTP-bound Ras and then detected on Western blot with a Ras antibody. Total Ras was detected in the same lysates to ensure equal
amounts of Ras in the experiment (lower panel). (C) ANBL-6 cells were grown in serum-free media in the presence of 0.1 ng⁄mL IL-6 with or
without the MEK1⁄2 inhibitors PD98059 or U126 for 3 d before estimation of DNA synthesis. Error bars represent SEM of triplicate measure-
ments. * Denotes statistically signiﬁcant difference from the situation without inhibitors (P < 0.05).
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ed the cells over night with anti-HGF serum to increase
c-Met expression before addition of IL-6 for 10 min with
or without the presence of the c-Met kinase inhibitor as
indicated in Fig. 6A,B. IL-6 induced low phosphoryla-
tion of tyrosine 542 on Shp2 under these conditions
(Fig. 6A left hand panels). In contrast, HGF induced
low but detectable phosphorylation of Gab1. Impor-
tantly, in the presence of HGF, the phosphorylation of
Shp2 was further increased with IL-6 (Fig. 6A right hand
panels). Furthermore, the Gab1 and Shp2 phosphoryla-
tion induced with the combination of HGF and IL-6
was markedly reduced in the presence of the c-Met
kinase inhibitor. These results indicate that the combina-
tion of HGF and IL-6 gave more pronounced activation
of Shp2 than either cytokine alone, suggesting that Shp2
activation induced by IL-6 also is dependent on c-Met
activation.
IL-6 has been reported to phosphorylate the IGF-1
receptor as basis for synergy between IL-6 and IGF-1
(32). Phosphorylation of c-Met induced by IL-6 could
have been an explanation for potentiation of Shp2 phos-
phorylation in ANBL-6 cells. However, this seemed not
to be the case (Fig. 6B).
To see if Shp2 activation was involved in activation of
p44⁄42 MAPK activation, we tested the effect of the
novel Shp2-inhibitor NSC-87877. This inhibitor binds to
the catalytic cleft of Shp2 and inhibits both basal, and
EGF-induced Shp2 phosphatase activity as well as EGF-
induced p44⁄42 MAPK phosphorylation which is known
to be dependent on Shp2 (33). In the presence of IL-6
and endogenous HGF, NSC-87877 inhibited phosphory-
lation of p44⁄42 MAPK in ANBL-6 cells in a dose-
dependent manner, without affecting the phosphorylation
of STAT3 (Fig. 6C). These results suggest that whereas
Shp2 is involved in p44⁄42 MAPK activation, it has no
role in STAT3 phosphorylation which is entirely depen-
dent on IL-6 in this setting. Furthermore, the synergy
observed in Ras-MAPK signaling is dependent on the
synergy in phosphatase activity of Shp2.
Discussion
The main ﬁnding reported here is that IL-6-induced
proliferation may be dependent on c-Met signaling in
myeloma cells. The potentiating effect of HGF⁄c-Met on
IL-6 signaling could be explained by two mechanisms: (i)
IL-6 increased the level of c-Met on the cell surface of
myeloma cells making cells more sensitive to HGF; and
(ii) IL-6 relied on HGF⁄c-Met to fully activate the Ras-
MAPK pathway possibly through Shp2 activation.
HGF is found in bone marrow plasma of both healthy
subjects and myeloma patients (5), and bone marrow
stromal cells constitutively produce HGF (34). More-
over, syndecan-1 binds HGF on the surface of myeloma
cells (5) bringing HGF in close proximity of its receptor
c-Met. Immunohistochemical staining for HGF on bone
marrow biopsies revealed that plasma cells from almost
all myeloma patients stained positive for HGF (K. W.
Wader, unpublished data). In this context, the IL-6-
induced increase in c-Met expression as shown here may
become vital for HGF sensitivity and growth promotion
of the cells. This is in line with other reports indicating
that increase of c-Met expression enhances both the bio-
logic effects of HGF and c-Met signaling in various cell
types (35–37). A recent publication also indicates that
the level of c-Met expression is important for the survival
of myeloma cells as partly downregulation of c-Met lead
to myeloma cell death (38). Moreover, in vivo induction
IL-6                                  +     +                        +      + 
PHA-665752            +             +               +               + 
HGF  A 
B 
C 
pGab1, tyr 672 
Gab1 
pSHP2, tyr 580
SHP2 
SHP2 
pSHP2, tyr 542
NSC-87877 (µM)     –       2.5       5       10        25
phospho p44/42 MAPK 
pSTAT3 
p44/42 MAPK 
IL-6                                  +     +                        +      + 
PHA-665752            +             +               +               + 
HGF 
p-c-Met, tyr 1349 
c-Met 
Figure 6 HGF was necessary for Gab-1-Shp2 activation in ANBL-6
cells. (A) ANBL-6 cells were incubated overnight with a 1 : 750 dilu-
tion of anti-HGF serum (to inhibit autocrine HGF-stimulation and sub-
sequently increase c-Met expression), then washed, cultured with or
without 200 nM PHA-665752 for 15 min and stimulated for 10 min
with or without HGF (100 ng⁄mL) or IL-6 (1 ng⁄mL). Lysates were
prepared and subjected to Western blot analysis. Membranes were
probed with antibodies against phospho-Gab1 tyr 627, phospho-Shp2
tyr 580 or 542. After stripping of membranes, probing with antibodies
against total Gab-1 or total Shp2 were used to control gel loading. (B)
Cells were treated as in (A). Immunoblots were probed with an anti-
body detecting phosphorylated tyrosine 1349 of c-Met. After stripping
of the membrane, total c-Met level was detected with a c-Met-spe-
ciﬁc antibody. (C) ANBL-6 cells were preincubated with different con-
centrations of the Shp2-inhibitor NSC-87877 for 5 h and then
stimulated with 1 ng⁄mL IL-6 for 10 min. Immunoblots were probed
with antibodies against phospho-p44⁄42 MAPK or phospho-STAT3 tyr
705, stripped and reprobed with an antibody against total p44⁄42
MAPK.
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myeloma model 5T33MM, and this induction was
necessary for biological effects of IGF-1 in these experi-
ments (39).
Inhibiting c-Met had substantial effects on IL-6-
induced proliferation in four out of nine primary
samples, although the frequency of this mechanism in
primary myeloma patients is hard to estimate due to the
low numbers of samples. These results are intriguing in
the light of the work of Chng et al. (9). They describe a
cluster of hyperdiploid patients with high expression of
HGF and IL-6 suggesting biologic importance of these
cytokines in these patients. As part our routine check on
MM patients, we screen for the genetic aberrations
denoted in Table 1. These data are not sufﬁcient to des-
ignate patients to the hyperdiploid group or even less to
the HGF⁄IL-6 subgroup of hyperdiploid myeloma. Nev-
ertheless, response to c-Met inhibition was present in
patients with t(6; 14) or t(11; 14) or without IgH translo-
cations. This suggests response in non-hyperdiploid (and
thus not exclusively in hyperdiploid) cases because IgH
translocations are strongly associated with non-hyperdip-
loid myeloma and a rare event in hyperdiploid patients
(40, 41). Further studies are necessary to see, if hyperdip-
loid patients with high HGF- and IL-6-expression are
subjected to synergy between IL-6 and HGF, and if they
can beneﬁt from c-Met inhibition.
The potentiating effect of c-Met signaling in IL-6-
induced p44⁄42 MAPK activation in ANBL-6 cells was
intriguing and a novel observation. Neither HGF nor
IL-6 alone could induce Ras-MAPK signaling, but the
combination of HGF and IL-6 was necessary to activate
this pathway. The Ras-MAPK pathway is a major regu-
lator of cell proliferation, and has previously been shown
to be important for myeloma cell proliferation in vitro
and in vivo (30). However, the role of c-Met as a regula-
tor of IL-6-induced Ras-MAPK signaling has to our
knowledge not been shown in myeloma cells before.
The synergy between IL-6 and c-Met in ANBL-6 cells
was also evident at the level of Shp2 phosphorylation.
Thus, the synergy between IL-6 and HGF must converge
on Shp2 or be a result of synergy upstream of Shp2. IL-
6 did not induce phosphorylation of c-Met or Gab1 as
HGF did while IL-6 treatment resulted in phosphoryla-
tion of Shp2. Thus, there may be two ways in which
Shp2 can be phosphorylated: IL-6 may induce Shp2
phosphorylation on tyrosine 542 whereas c-Met signaling
potentiates the phosphorylation of both tyrosine 542 and
580 in a process dependent on Gab1. There is some sup-
port for such a mechanism in the literature as it has been
shown that Shp2 can directly bind to the cytoplasmic tail
of gp130 and become activated (42). Furthermore, IL-6
has previously also been shown to phosphorylate Shp2
in the myeloma cell line MM1.S (43). There is also
evidence that the double phosphorylation of Shp2 on ty-
rosines 542 and 580 is important for full catalytic activity
of Shp2 (44). The results presented here indicate that
both IL-6 and c-Met activation may be required for full
catalytic activity of Shp2.
Shp2 activation appeared to be necessary for the acti-
vation of p44⁄42 MAPK as the novel SHP2 inhibitor
NSC-87877 abrogated cytokine-mediated MAPK phos-
phorylation in ANBL-6. NSC-87877 is also known to
inhibit the tyrosine phosphatase Shp1; however, Shp1
has been shown to negatively control receptor signaling
(45), and even to reduce MAPK-activation in thyroid
carcinoma and neurons (46, 47).
Here, we show that c-Met signaling may be important
in myeloma cell proliferation induced by IL-6. Targeting
HGF⁄c-Met may therefore attenuate growth promotion
by other growth factors than HGF, and c-Met signaling
may be a target for therapy also in multiple myeloma.
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